On Tuesday, 28 September, the European Commission entered the final phase of the work to accomplish in preparation for revising legislation on medicines for rare diseases (141/2000) and on medicines for paediatric use (1901/2006).
This revision was specifically promised by the European Commission in the context of its pharmaceutical strategy (see EUROPE B12609A10).
After presenting its roadmap on this initiative and launching an initial request for comment last March...